TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Cancer Panel: Lack Of Genetic Basis For Race Presents Dilemma For Studies; Data Collection Must Include Socioeconomic Measures, Report To Clinton Says March 20, 1998
